Moderna's Flu Vaccine Candidate, mRNA-1010, Is More Effective Than GSK's Long-Approved Jab...

I suppose the central question now is whether Moderna can be ready at scale here in the US for this Fall's flu season. This is very good news for the company whose stock (I believe) is worth more than double its current exchange-traded pricing.

Moderna is up almost 3% -- in the first hour of trading, this morning -- on this news:

. . .Moderna’s vaccine, mRNA-1010, was 26.6 per cent more effective than GSK’s approved shot in the overall study population, which included 40,805 adults aged 50 years and older, Moderna said.

The shot was shown to be 27.4 per cent more effective than GSK’s shot in adults 65 years and older – a group that is usually at highest risk to flu.

“The severity of this past flu season underscores the need for more effective vaccines,” CEO Stéphane Bancel said.

Moderna said its mRNA-based shot has the potential advantage to more precisely match circulating strains and support rapid response in a future influenza pandemic.

The shot had previously generated a stronger immune response against all four A and B strains of the influenza virus compared to traditional flu shots in a late-stage trial in 2023. . . .

Yep -- we are leading with a "power alley" item, to start the short holiday week -- here in the US. Onward, smiling. . . .

नमस्ते